ArticleCancer biology & medicine2024

Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancer.

Qi Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.